387 related articles for article (PubMed ID: 33169506)
1. Neoadjuvant selpercatinib for advanced medullary thyroid cancer.
Jozaghi Y; Zafereo M; Williams MD; Gule-Monroe MK; Wang J; Grubbs EG; Vaporciyan A; Hu MI; Busaidy N; Dadu R; Waguespack SG; Subbiah V; Cabanillas M
Head Neck; 2021 Jan; 43(1):E7-E12. PubMed ID: 33169506
[TBL] [Abstract][Full Text] [Related]
2. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve
Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E
Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032
[TBL] [Abstract][Full Text] [Related]
3. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
4. Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib.
Elisei R; Ciampi R; Matrone A; Prete A; Gambale C; Ramone T; Simeakis G; Materazzi G; Torregrossa L; Ugolini C; Romei C
J Clin Endocrinol Metab; 2022 Jul; 107(8):2195-2202. PubMed ID: 35616103
[TBL] [Abstract][Full Text] [Related]
5. Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial.
Wirth LJ; Robinson B; Boni V; Tan DSW; McCoach C; Massarelli E; Hess LM; Jen MH; Kherani J; Olek E; Subbiah V
Oncologist; 2022 Feb; 27(1):13-21. PubMed ID: 34516023
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
[TBL] [Abstract][Full Text] [Related]
7. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
[TBL] [Abstract][Full Text] [Related]
8. Initial Experiences of Selective RET Inhibitor Selpercatinib in Adults with Metastatic Differentiated Thyroid Carcinoma and Medullary Thyroid Carcinoma: Real-World Case Series in Korea.
Baek HS; Ha J; Ha S; Bae JS; Jung CK; Lim DJ
Curr Oncol; 2023 Mar; 30(3):3020-3031. PubMed ID: 36975442
[TBL] [Abstract][Full Text] [Related]
9. Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Subbiah V; Hu MI; Mansfield AS; Taylor MH; Schuler M; Zhu VW; Hadoux J; Curigliano G; Wirth L; Gainor JF; Alonso G; Adkins D; Godbert Y; Ahn MJ; Cassier PA; Cho BC; Lin CC; Zalutskaya A; Barata T; Trask P; Scalori A; Bordogna W; Heinzmann S; Brose MS
Thyroid; 2024 Jan; 34(1):26-40. PubMed ID: 38009200
[No Abstract] [Full Text] [Related]
10. A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion.
Wijewardene A; Bastard K; Wang B; Gild M; Luxford C; Gill A; Robinson B; Bullock M; Clifton-Bligh R
Thyroid; 2023 Jan; 33(1):119-125. PubMed ID: 36416226
[No Abstract] [Full Text] [Related]
11. The Evolving Treatment Landscape of Medullary Thyroid Cancer.
Laganà M; Cremaschi V; Alberti A; Vodopivec Kuri DM; Cosentini D; Berruti A
Curr Treat Options Oncol; 2023 Dec; 24(12):1815-1832. PubMed ID: 37979019
[TBL] [Abstract][Full Text] [Related]
12. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
13. Selpercatinib: First Approval.
Markham A
Drugs; 2020 Jul; 80(11):1119-1124. PubMed ID: 32557397
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Selpercatinib in
Wirth LJ; Sherman E; Robinson B; Solomon B; Kang H; Lorch J; Worden F; Brose M; Patel J; Leboulleux S; Godbert Y; Barlesi F; Morris JC; Owonikoko TK; Tan DSW; Gautschi O; Weiss J; de la Fouchardière C; Burkard ME; Laskin J; Taylor MH; Kroiss M; Medioni J; Goldman JW; Bauer TM; Levy B; Zhu VW; Lakhani N; Moreno V; Ebata K; Nguyen M; Heirich D; Zhu EY; Huang X; Yang L; Kherani J; Rothenberg SM; Drilon A; Subbiah V; Shah MH; Cabanillas ME
N Engl J Med; 2020 Aug; 383(9):825-835. PubMed ID: 32846061
[TBL] [Abstract][Full Text] [Related]
15. A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.
Seib CD; Beck TC; Kebebew E
Surg Oncol Clin N Am; 2023 Apr; 32(2):233-250. PubMed ID: 36925182
[TBL] [Abstract][Full Text] [Related]
16. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
17. Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report.
Matrone A; Prete A; Sartini MS; Elisei R
Ann Oncol; 2021 Nov; 32(11):1447-1449. PubMed ID: 34419556
[No Abstract] [Full Text] [Related]
18. Phase 3 Trial of Selpercatinib in Advanced
Hadoux J; Elisei R; Brose MS; Hoff AO; Robinson BG; Gao M; Jarzab B; Isaev P; Kopeckova K; Wadsley J; Führer D; Keam B; Bardet S; Sherman EJ; Tahara M; Hu MI; Singh R; Lin Y; Soldatenkova V; Wright J; Lin B; Maeda P; Capdevila J; Wirth LJ;
N Engl J Med; 2023 Nov; 389(20):1851-1861. PubMed ID: 37870969
[TBL] [Abstract][Full Text] [Related]
19. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
20. Selpercatinib for adult patients with locally advanced or metastatic RET-altered solid tumors.
Le D; Konda B
Expert Rev Anticancer Ther; 2023; 23(11):1117-1122. PubMed ID: 37795873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
